10-Q: Standard BioTools Divests SomaScan Business to Illumina

Standard BioTools Inc. reported a reduced net loss in Q2 2025, driven by lower operating expenses and the strategic divestiture of its SomaScan business to Illumina for up to $425 million.

Summary

• Net loss for the three months ended June 30, 2025, was $33.459 million, an improvement from $45.718 million in the prior year period.
• Net loss per share for the quarter was $0.09, down from $0.12 in the same period last year.
• Total revenue from continuing operations for Q2 2025 was $21.762 million, a 3% decrease from $22.492 million in Q2 2024.
• Product revenue from instruments decreased by 26% to $5.215 million in Q2 2025, while consumables revenue increased by 18% to $10.458 million.
• Gross profit from continuing operations increased by 2% to $10.628 million in Q2 2025, with gross margin improving to 48.8% from 46.1%.
• Operating expenses from continuing operations decreased by 11% to $36.325 million in Q2 2025, primarily due to significant reductions in restructuring and transaction/integration expenses.
• The SomaScan Business was classified as discontinued operations following a Stock Purchase Agreement with Illumina, Inc. on June 22, 2025.
• Illumina will acquire the SomaScan Business for aggregate cash consideration of up to $425 million, comprising an upfront payment of $350 million and up to $75 million in earnout payments.
• Net cash used in operating activities for the six months ended June 30, 2025, significantly decreased to $50.951 million from $101.526 million in the prior year period.
• Cash, cash equivalents, and short-term investments totaled $237.1 million as of June 30, 2025.

Sentiment

Score: 7

Explanation: The strategic divestiture of the SomaScan business provides a significant cash infusion and allows the company to focus on its core profitable segments. While revenue from continuing operations declined, operational efficiencies led to a reduced net loss and improved cash burn. However, ongoing litigation and the uncertainty surrounding the divestiture's closing temper the overall positive sentiment.

Positives

• Net loss significantly decreased for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved financial performance.
• Gross profit increased and gross margin improved for both the three and six months ended June 30, 2025, reflecting a favorable product mix with strong consumables growth.
• Operating expenses saw substantial reductions, particularly in restructuring and transaction/integration expenses, demonstrating improved operational efficiency.
• The divestiture of the SomaScan Business to Illumina for up to $425 million provides a significant cash infusion and allows for strategic focus on core mass cytometry and microfluidics businesses.
• Net cash used in operating activities decreased by $50.6 million for the six months ended June 30, 2025, indicating a substantial improvement in cash burn.
• The company fully repaid its outstanding term loan facility and convertible notes during 2024, resulting in negligible interest expense in the current period.

Negatives

• Total revenue from continuing operations declined by 3% for the three months and 5% for the six months ended June 30, 2025, compared to prior year periods.
• Instrument revenue decreased by 26% in Q2 2025, primarily due to lower unit sales of the CyTOF XT mass cytometry instrument.
• Services and other revenue also declined by 8% in Q2 2025 and 11% for the six months ended June 30, 2025.
• Selling, general and administrative (SG&A) expenses increased by 13% for both the three and six months ended June 30, 2025, due to certain personnel-related and corporate overhead costs becoming 'stranded' with continuing operations after the SomaScan divestiture.
• Accumulated deficit increased to $1,245.1 million as of June 30, 2025, from $1,185.6 million at December 31, 2024.

Risks

• The consummation of the Transaction with Illumina is subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act approval, and there is no assurance it will be completed.
• The announcement and pendency of the Transaction, or its failure to close, could adversely affect stock price, business operations, and financial condition due to employee uncertainty, management distraction, and potential negative publicity.
• The company may not fully realize the expected operating and capital cost savings from the Transaction, leading to increased costs, decreased expected revenues, and further diversion of management time.
• Delays in completing the Transaction could reduce or eliminate the expected benefits and divert management focus from other opportunities or day-to-day operations.
• Ongoing stockholder litigation, including a denied motion to dismiss in the Delaware Court of Chancery, could result in significant costs and divert management's attention and resources.
• A lawsuit filed by Shareholder Representative Services LLC (SRS) against SomaLogic alleges breaches of the Palamedrix Merger Agreement, seeking up to $17.5 million in sales milestones, which could result in significant costs.

Future Outlook

The company expects the divestiture of the SomaScan Business to Illumina to close in the first half of 2026, subject to customary closing conditions. Management plans to continue significant investments in research and development, focusing on advancing existing products and services, and expanding its proteomic content, including mass cytometry antibody panels and single-cell proteomics database. The company also aims to optimize its cost structure for the remaining business and expects existing liquidity to be sufficient for at least the next 12 months.

Management Comments

• Committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team.
• Empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas.
• Solutions are designed to unlock complex biological information across plasma, single-cell and spatial proteomics, as well as genomic analyses, enabling researchers to explore disease mechanisms with unprecedented depth and precision.
• Advanced platforms—CyTOF, Hyperion, and Biomark—empower scientists to generate high-content data across therapeutic areas, from immuno-oncology to neurology and infectious diseases.

Industry Context

The divestiture of the SomaScan business allows the company to streamline its operations and focus on its core mass cytometry and microfluidics technologies. This strategic move aligns with a broader industry trend where life science tool companies may specialize in specific high-growth areas or divest non-core assets to enhance efficiency and market focus. The collaboration agreement with Illumina, even post-divestiture, highlights the increasing importance of strategic partnerships and intellectual property licensing in the competitive proteomics and genomics sectors.

Comparison to Industry Standards

• NA

Legal Proceedings

• Stockholder litigation filed in the District of Delaware (December 12, 2023) and Delaware Court of Chancery (December 13, 2023) related to the SomaLogic merger, alleging Breach of Fiduciary Duty and materially deficient registration statement. A motion to dismiss in the Delaware Court of Chancery was denied on August 7, 2025.
• Settlement of previously outstanding litigation with a former SomaLogic stockholder in February 2024, involving the relinquishment of 422,048 shares of common stock.
• Settlement of litigation with former SomaLogic stockholders in May 2024 for $6.2 million, including repurchase of approximately 1.84 million shares and a cash payment.
• A demand pursuant to Section 220 of the Delaware General Corporation Law was received on June 4, 2024, from a stockholder to inspect books and records related to Series B Preferred Stock conversion.
• Shareholder Representative Services LLC (SRS) filed suit against SomaLogic on July 3, 2025, alleging breaches of the Palamedrix Merger Agreement, specifically failure to invest in technology that could have led to $17.5 million in sales milestones. SomaLogic moved to compel arbitration/dismiss on August 4, 2025.

Related Party Transactions

• Eli Casdin, a board member and principal stockholder, received 3,807 shares of common stock, 3,807 RSUs, and 144,088 options in exchange for SomaLogic equity awards during the Merger.
• Casdin Partners Master Fund, L.P. and Casdin Private Growth Equity Fund, L.P. received 11,246,525 and 2,744,219 shares of common stock, respectively, in exchange for SomaLogic common stock, indirectly beneficially owned by Mr. Casdin.
• Warrants held by CMLS Holdings II LLC (indirectly beneficially owned by Mr. Casdin) converted into the right to receive 4,824,802 shares of common stock, and CMLS LLC also received 7,548,000 shares of common stock in exchange for SomaLogic common stock.
• On March 18, 2024, Casdin and its affiliates converted all outstanding Series B-1 Preferred Stock into 46,465,458 shares of common stock.

Stakeholder Impact

• Shareholders: Potential for increased value from strategic focus and cash infusion, but also risk of stock price volatility due to divestiture uncertainties and ongoing litigation. The share repurchase program could provide some support.
• Employees: Uncertainty regarding future roles due to the divestiture and ongoing restructuring activities, though the company aims for operational efficiencies.
• Customers: Continued access to the company's core mass cytometry and microfluidics products and services, with potential for enhanced offerings due to focused R&D investments.
• Suppliers: Potential for modified business relationships due to the divestiture and changes in the company's operational footprint.
• Creditors: Improved liquidity and reduced debt obligations enhance the company's financial stability.

Next Steps

• Complete the divestiture of the SomaScan Business to Illumina, expected in the first half of 2026.
• Continue to invest significantly in research and development efforts for the remaining mass cytometry and microfluidics businesses.
• Enhance single-cell and spatial proteomics offerings through continuous improvements to proteomics instruments.
• Increase the number of protein reagents for commercial availability, focusing on expanding mass cytometry antibody panels and detection capabilities.
• Expand the single-cell proteomics database and artificial intelligence/machine learning analytics to drive deeper insights.
• Optimize the cost structure for the remaining business to realize additional cost savings.

Key Dates

Recommendation

The strategic divestiture of the SomaScan business is a significant positive, providing substantial cash and allowing the company to focus on its core profitable segments. This, combined with improved operational efficiency and reduced cash burn, strengthens the balance sheet. However, the decline in revenue from continuing operations, the 'stranded costs' in SG&A, and the ongoing legal proceedings introduce considerable uncertainty. The stock is in a transitional phase, and while the long-term outlook may improve with a more focused strategy, current challenges warrant a cautious 'hold' position until the benefits of the divestiture are fully realized and operational stability is demonstrated.

Keywords

Life Science Tools, Proteomics, Genomics, Mass Cytometry, Microfluidics, SomaScan, Illumina, Divestiture, SEC Filing, 10-Q, Financial Results, Biotechnology, Diagnostics, LAB